DALLAS, June 06, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALYâ€) today announced a presentation scheduled next week on Tuesday, June 11th were management will present KALY’s mobile cannabis extraction capacity to be utilized in its recently announced contract with a New York State Licensed Hemp Cultivation Operation anticipated to generate an estimated $5 million in revenue for KALY. The presentation will include details on how the mobile cannabis extraction capacity will be utilized to potentially expand the $5 million contract into potentially more than $20 million in similar contracts.
KALY owns and operates a U.S. Patented Cannabis
Extraction Process. In addition to its direct cannabis
extraction business, the company is advancing biotechnology
research for the future production of cannabis extract centric
pharmaceuticals and at the same time, the company is currently
generating revenue from the sale of CBD infused consumer
products.
KALY is primarily a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
a proprietary cannabinoid product platform in a broad range of
disease areas. In the fourth quarter of last year, 2018, KALY
acquired NCM Biotech (NCMB). In NCMB’s four years of
operations, the company has established a leading position in the
development of plant-derived cannabinoid therapeutics through a
proven drug discovery and patented development process. The
resulting intellectual property portfolio and the established
regulatory and manufacturing expertise have created a significant
opportunity. KALY has a deep pipeline of cannabinoid product
candidates including four distinct compounds. KALY has
completed the first stage of clinical development and testing for a
Chronic Obstructive Pulmonary Disease (COPD) therapy and is
currently conducting phase one development and trials for compounds
targeting Cancer Pain Management, Type 2 Diabetes and
Epilepsy.
KALY is not relying on its biopharmaceutical development strategy
alone to insure the company’s long-term success. With the
popularity of cannabis extracts for infusion into various consumer
products, KALY’s patented extraction process offers arguably the
highest quality extract to the infusion market. Drawing on
KALY’s patented cannabis extraction expertise, in addition to
winning the $5 million extraction contract mentioned above, KALY
has partnered with Puration (PURA) to lend
its extraction expertise in the production of EVERx CBD Sports
Water, the leading CBD infused beverage for the sports nutrition
market. KALY has also introduced its own CBD confections
line, Hemp4mula with CBD infused gum already on the market and
gummies on the way. Hemp4mula is available on the Ecommerce
site USMJ.com hosted by North American Cannabis Holdings, Inc.
(USMJ) (aka USMJ). KALY’s
non-pharmaceutical extraction revenue strategy offers a business
line that can stand alone, and at the same time provide KALY with
the long-term staying power to bring its cannabis extract
biopharmaceutical products to market.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459